Awakn Life Sciences Submits Clinical Trial Application for Phase III Trial Of AWKN-P001
AWAKN-P001 Is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for The Treatment of Severe Alcohol Use Disorder TORONTO, CANADA, Sept 6, 2023 – Awakn Life Sciences Corp. (NEO:…